JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Topotecan (SKF104864) is an inhibitor of topoisomerase 1 and semisynthetic analogue of camptothecin [1].
Topotecan (SKF104864) has been reported to have a potent antitumor activity against tumors in murine models. In addition, Topotecan has also shown the potent effect against intravenously implanted P388 leukemia and both intravenously and subcutaneously implanted Lewis lung carcinoma. Topotecan has noted the activity against subcutaneously implanted solid tumors including chemorefractory tumors and human colon carcinoma xenograft HT-29. Topotecan has been found to induce regressions in the lung tumor model (Lewis lung carcinoma and B16 melanoma), compared to camptothecin and 9-amino-camptothecin. In the preclinical toxicology studies, Topotecan has been revealed to have a concentration-dependent, reversible and limited toxoicity to rapidly proliferation tissues such as bone marrow and gastro-intestinal epithelium [1].
References:[1] Creemers GJ1, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev. 1994 Jan;20(1):73-96.
Cell lines
Human glioma cell lines U251, U87, GSCs-U251 and GSCs-U87
Reaction Conditions
0.02, 0.2, 2, 20 or 40 μmol/L topotecan for 12, 24 or 48 h incubation
Applications
Topotecan obviously inhibited proliferation of not only human glioma cells but also glioma stem cells in a dose- and time-dependent manner. In addition, topotecan (3 μmol/L, 24 h) induced cell cycle arrest in G0/G1 and S phases and promoted apoptosis.
Animal models
Mouse models of aggressive pediatric solid tumor
Dosage form
1 mg/kg
Once daily by oral gavage
Metronomic administration of topotecan and pazopanib showed a statistically significant antitumor activity compared with respective single agents in pediatric tumor mouse models, representing a valid option as a maintenance therapy in aggressive pediatric solid tumors.
Note
The technical data provided above is for reference only.
References:
1. Zhang FL, Wang P, Liu YH, et al. Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells. PLoS One, 2013, 8(11): e81815.
2. Kumar S, Mokhtari RB, Sheikh R, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clinical Cancer Research, 2011, 17(17): 5656-5667.
